ASH 2020 | Daratumumab reduces carfilzomib-related cardiac toxicities in R/R myeloma
Evangelos Terpos
• 20 Nov 2020
Evangelos Terpos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece discusses the findings of an observational study of daratumumab’s potential to lessen carfilzomib-related cardiovascular toxicity in relapsed/refractory (R/R) multiple myeloma patients. Following the recording of baseline cardiotoxicity risk factors and performance of a cardiac ultrasound, patients were given carfilzomib and dexamethasone (Kd), with or without daratumumab (data). The results suggest a role for dara in preserving cardiac function and preventing CVAEs, warranting additional mechanistic investigation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
